苯并咪唑作为药物设计和发现中的优势骨架。
Benzimidazole as a Privileged Scaffold in Drug Design and Discovery.
机构信息
Institute of Pharmaceutical Research, GLA University, Mathura, Uttar Pradesh, 281406, India.
出版信息
Curr Top Med Chem. 2024;24(17):1504-1528. doi: 10.2174/0115680266314704240522112439.
Benzimidazole is a privileged drug design and discovery scaffold with various pharmacological activities, including antimicrobial, anticancer, antitubercular, anti-inflammatory, antidiabetic, antihypertensive, antimalarial, and many more. This scaffold can be observed in the structure of numerous FDA-approved drugs and employed in medicinal chemistry to develop novel bioactive compounds through rational drug design. Its broad pharmacological significance is due to physicochemical attributes, including H-bond donor-acceptor efficiency, π-π stacking interactions, and hydrophobic interactions; these characteristics enable benzimidazole derivatives to bind with macromolecules efficiently. This article emphasizes mechanisms, SAR, and docking studies to unveil benzimidazole's various active hybrids accountable for diversified activities. It will assist researchers in strategically designing various novel benzimidazole-endowed hybrids to develop clinically active therapeutic candidates.
苯并咪唑是一种具有多种药理活性的药物设计和发现的优势骨架,包括抗菌、抗癌、抗结核、抗炎、抗糖尿病、抗高血压、抗疟疾等。该骨架可以在许多 FDA 批准的药物的结构中观察到,并在药物化学中用于通过合理药物设计开发新型生物活性化合物。其广泛的药理意义归因于物理化学特性,包括氢键供体-受体效率、π-π 堆积相互作用和疏水相互作用;这些特性使苯并咪唑衍生物能够有效地与大分子结合。本文强调了机制、SAR 和对接研究,以揭示苯并咪唑的各种活性杂合体能产生多样化的活性。它将帮助研究人员战略性地设计各种新型苯并咪唑赋予的杂合药物,以开发具有临床活性的治疗候选药物。